CVE intelligence and bounded remediation

CVE-2020-10627 — Insulet Omnipod Insulin Management System Firmware security vulnerability

High CVSS 8.1

Insulet Omnipod Insulin Management System insulin pump product ID 19191 and 40160 is designed to communicate using a wireless RF with an Insulet manufactured Personal Diabetes Manager device. This wireless RF communication protocol does not properly implement authentication or authorization. An attacker with access to one of the affected insulin pump models may be able to modify and/or intercept data. This vulnerability could also allow attackers to change pump settings and control insulin delivery.

Severity
High
CVSS
8.1 (3.1)
Published
2021-12-01
CISA KEV
Not currently listed
Ecosystem
operating-system
Weaknesses
CWE-284

Affected products

  • insulet / omnipod_insulin_management_system_firmware

Matched remediation archetype

Authorization bypass, IDOR, and cross-tenant access

This catalog composition supplies bounded fallback guidance. Explicitly reviewed curated workflows load with the complete record below.

Check exposure

  • Map object and action authorization checks across API, UI, batch, import/export, and background-job paths.
  • Identify tenant, ownership, role, and policy boundaries for affected resources and administrative operations.
  • Use synthetic fixtures to compare intended access matrices without accessing another user's real data.

Remediate safely

  • Enforce server-side authorization at each resource access and state transition using the authenticated principal and trusted tenant context.
  • Scope data queries by tenant and ownership; treat client-supplied identifiers, roles, and policy claims as untrusted.
  • Add deny-by-default policy tests for horizontal and vertical access across every affected transport.

Authoritative sources

Complete CVE record and remediation plan

The detailed catalog view below loads this exact record, its source evidence, and the full seven-phase agentic change plan.